| Patient | Charlotte Brontë |
|---|---|
| Date of birth | 1987-04-21 |
| Identifiers | MRN HR-NI025-SYN; SSN (made up) 000-25-3804 |
| Document date | 2026-02-10 |
| Author | Eleanor Thwaite, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Review at 11 weeks, nine days after discharge from an admission for hyperemesis gravidarum. [S]
Ms. Brontë returns at 11 weeks 1 day. After the sick visit she was admitted for three nights for intravenous saline with potassium, thiamine, magnesium, ondansetron, and enoxaparin, and went home nine days ago keeping down fluids, food, and tablets. She takes ondansetron 4 mg every 8 hours, doxylamine-pyridoxine four tablets a day, and thiamine 100 mg three times a day. She now vomits once a day or less and eats five small meals a day. Her PUQE-24 score is 9. She has mild constipation since starting ondansetron, which she manages with fluids, prunes, and oat bran. She has had no headache, palpitations, pain, or bleeding. She felt low and frightened in the hospital and is now more hopeful. The planned electrolyte check within a week of discharge was not done; blood was drawn today. [S]
| Element | Detail |
|---|---|
| Hospital course | Three nights: intravenous fluids, potassium, magnesium, thiamine, ondansetron, enoxaparin |
| Interval change | Vomiting once a day or less; five small meals a day |
| PUQE-24 | 9 (moderate), down from 14 |
| Side effects | Mild constipation on ondansetron |
| Mood | More hopeful; EPDS 9 |
| System | Result | Finding |
|---|---|---|
| Gastrointestinal | Positive | Nausea in the mornings; vomiting once a day or less; mild constipation |
| Cardiovascular | Negative | No palpitations or fainting |
| Neurological | Negative | No headache, confusion, or unsteadiness |
| Genitourinary | Negative | No bleeding or urinary symptoms |
| Psychiatric | Positive | Was low and frightened in hospital; more hopeful now; no thoughts of self-harm |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Folic acid 0.4 mg oral tablet, one tablet by mouth daily (replacing an iron-containing prenatal vitamin while nausea is severe) | One tablet by mouth daily | Oral route | 2026-01-13 | active | S |
| Doxylamine 10 mg and pyridoxine 10 mg delayed-release tablet, two tablets by mouth at bedtime | Two tablets by mouth at bedtime | Oral route | 2026-01-13 to 2026-01-20 | completed | S |
| Doxylamine 10 mg and pyridoxine 10 mg delayed-release tablet, one tablet in the morning, one mid-afternoon, and two at bedtime (four a day) | One tablet in the morning, one mid-afternoon, and two at bedtime | Oral route | 2026-01-20 | active | S |
| Metoclopramide 10 mg oral tablet, one tablet by mouth three times a day before meals | One tablet by mouth three times a day, 30 minutes before meals | Oral route | 2026-01-20 to 2026-01-29 | completed | S |
| Sodium chloride 0.9% with potassium chloride 20 mmol per liter, 1000 mL intravenously over 8 hours | 1000 mL over 8 hours, guided by daily electrolytes | Intravenous route | 2026-01-29 to 2026-02-01 | completed | S |
| Thiamine 100 mg intravenously daily, the first dose before any dextrose | 100 mg intravenously once daily; first dose before any dextrose-containing fluid | Intravenous route | 2026-01-29 to 2026-02-01 | completed | S |
| Ondansetron 4 mg intravenously every 8 hours | 4 mg by slow intravenous injection every 8 hours | Intravenous route | 2026-01-29 to 2026-02-01 | completed | S |
| Enoxaparin 20 mg subcutaneously once daily during the admission (weight under 50 kg) | 20 mg (0.2 mL) subcutaneously once daily while in hospital | Subcutaneous route | 2026-01-29 to 2026-02-01 | completed | S |
| Magnesium sulfate 2 g in 50 mL intravenously over 1 hour, once | 2 g intravenously over 1 hour, one dose | Intravenous route | 2026-01-29 to 2026-01-29 | completed | S |
| Ondansetron 4 mg orally disintegrating tablet, one tablet every 8 hours | One tablet on the tongue every 8 hours | Oral route | 2026-02-01 to 2026-02-24 | completed | S |
| Thiamine 100 mg oral tablet, one tablet by mouth three times a day | One tablet by mouth three times a day while intake is poor | Oral route | 2026-02-01 to 2026-02-24 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-02-10 | Body height | 152 | cm | S |
| 2026-02-10 | Body weight | 43.6 | kg | S |
| 2026-02-10 | Body mass index (BMI) [Ratio] | 18.9 | kg/m2 | S |
| 2026-02-10 | Systolic blood pressure | 104 | mm[Hg] | S |
| 2026-02-10 | Diastolic blood pressure | 64 | mm[Hg] | S |
| 2026-02-10 | Heart rate | 86 | /min | S |
| 2026-02-10 | Respiratory rate | 14 | /min | S |
| 2026-02-10 | Body temperature | 36.7 | Cel | S |
| 2026-02-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-02-10 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-02-10 | Potassium [Moles/volume] in Serum or Plasma | 4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-02-10 | Chloride [Moles/volume] in Serum or Plasma | 101 | mmol/L | 98-107 mmol/L | Normal | S |
| 2026-02-10 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 25 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-02-10 | Urea nitrogen [Mass/volume] in Serum or Plasma | 9 | mg/dL | 6-20 mg/dL | Normal | S |
| 2026-02-10 | Creatinine [Mass/volume] in Serum or Plasma | 0.55 | mg/dL | 0.4-0.9 mg/dL | Normal | S |
| 2026-02-10 | Glucose [Mass/volume] in Serum or Plasma | 82 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-02-10 | Magnesium [Mass/volume] in Serum or Plasma | 1.9 | mg/dL | 1.7-2.2 mg/dL | Normal | S |
| 2026-02-10 | Phosphate [Mass/volume] in Serum or Plasma | 3.4 | mg/dL | 2.5-4.5 mg/dL | Normal | S |
| 2026-02-10 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 31 | U/L | 7-35 U/L | Normal | S |
| 2026-02-10 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 10-35 U/L | Normal | S |
| 2026-02-10 | Total score [EPDS] | 9 | {score} | S |
Vital signs recorded on 2026-02-10; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Slight; better color; comfortable |
| Hydration | Moist mucous membranes; pulse 86 |
| Abdomen | Soft and non-tender; uterus just palpable above the pubic bone |
| Fetal | Fetal heart heard by handheld Doppler at 158 per minute |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| First pregnancy at 38 (elderly primigravida), single live intrauterine pregnancy dated by ultrasound at 7 weeks 1 day | active | confirmed | O09.519 | S — Synthetic modern prenatal care anchored to the documented report that she was pregnant when she died; the pregnancy itself is questioned in one source (CLM-0019). |
| Nausea and vomiting of pregnancy, moderate (PUQE-24 score 10), with early weight loss, under evaluation for hyperemesis gravidarum | resolved | confirmed | O21.9 | S — Synthetic presenting concern at the index visit, superseded by the hyperemesis gravidarum diagnosis at the sick visit; her documented "perpetual nausea" is D and the hyperemesis reading of it is R. |
| Hyperemesis gravidarum with metabolic disturbance: unable to keep fluids down, 7.4 percent weight loss, dehydration, hypokalemia, hyponatremia, hypochloremic alkalosis, low magnesium, and raised transaminases; PUQE-24 score 14 | active | confirmed | O21.1 | S — Synthetic modern diagnosis linked to her documented final illness and the retrospective hyperemesis interpretation; it is not asserted as her historical diagnosis. |
| Gestational transient thyrotoxicosis: suppressed TSH and mildly raised free T4 with hyperemesis, no goiter, eye signs, or tremor; no treatment needed | active | confirmed | O99.281 | S — Synthetic finding that teaches the thyroid tests in hyperemesis; it echoes no documented illness. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PUQE-24 score (recorded in the note; no LOINC code found) | Every visit while nausea and vomiting last | Completed today | 9 (moderate), down from 14 at the sick visit |
| Examination | Weight against pre-pregnancy weight (46.0 kg), pulse, blood pressure, and hydration | Every visit while nausea and vomiting last | Completed today | 43.6 kg, up 1.0 kg; pulse 86; well hydrated |
| Laboratory | Electrolytes, urea nitrogen, creatinine, and glucose | When vomiting is moderate or severe, daily while on intravenous fluids, and until stable on oral intake | Completed today | Normal |
| Laboratory | Electrolytes within a week of discharge | Once, within seven days of discharge | Deferred | Missed: the check planned for within a week of discharge was not booked, and the first post-discharge electrolytes were drawn today, nine days after discharge. No harm: all results today are normal. Corrective action: discharge orders for hyperemesis now include a booked laboratory appointment |
| Laboratory | Magnesium and phosphate (refeeding risk) | During admission and after refeeding begins | Completed today | Magnesium 1.9 and phosphate 3.4 mg/dL: normal; no refeeding drop |
| Laboratory | ALT and AST | Until normal if raised | Completed today | ALT 31 and AST 24 U/L: normal |
| Laboratory | TSH and free T4 | In hyperemesis gravidarum; repeat at 16 to 18 weeks if suppressed | Due | Suppressed at the sick visit; repeat planned at 16 to 18 weeks |
| Medication safety | Antiemetic effects: constipation, headache, and palpitations with ondansetron; drowsiness with doxylamine-pyridoxine | Every visit and after each change | Completed today | Mild constipation only |
| Medication safety | Thiamine while intake is poor | From admission until regular meals | Completed today | 100 mg three times a day; no signs of Wernicke encephalopathy |
| Examination | Venous thromboembolism risk assessment | At every admission and discharge, and at 28 weeks | Completed today | Age over 35 is her only persisting risk factor; no prophylaxis now |
| Survey | Perinatal mood screen | Each trimester and after any admission | Completed today | EPDS 9; item 10 scored 0 |
| Laboratory | Cell-free DNA screening | From 10 weeks, as she chose | Ordered | Drawn today; result in about a week |
| Examination | Blood pressure | Every prenatal visit | Completed today | 104/64 mmHg |
| Examination | Fetal heart | Every prenatal visit | Completed today | 158 per minute by Doppler |
Goal progress:
Guideline basis: ACOG Practice Bulletin No. 189: Nausea and Vomiting of Pregnancy (2018); The Management of Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum (Green-top Guideline No. 69) (2024); Reducing the Risk of Thrombosis and Embolism during Pregnancy and the Puerperium (Green-top Guideline No. 37a) (2015); Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin, Number 226 (2020); Screening and Diagnosis of Mental Health Conditions During Pregnancy and Postpartum (Clinical Practice Guideline No. 4) (2023)
Follow-up: Prenatal visit with the nuchal translucency scan in two weeks, at 13 weeks. Next scheduled visit 2026-02-24: prenatal visit at 13 weeks with the nuchal translucency scan and the low-dose aspirin decision. [S]